Provectus Biopharmaceuticals Inc (PVCT)
0.1913
0.00 (0.00%)
USD |
OTCM |
May 02, 16:00
Provectus Biopharmaceuticals Net Income (Quarterly): -0.6634M for Dec. 31, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -0.6634M |
| September 30, 2023 | -0.7758M |
| June 30, 2023 | -0.8351M |
| March 31, 2023 | -0.8275M |
| December 31, 2022 | -0.7327M |
| September 30, 2022 | -0.7133M |
| June 30, 2022 | -1.078M |
| March 31, 2022 | -1.031M |
| December 31, 2021 | -1.239M |
| September 30, 2021 | -1.051M |
| June 30, 2021 | -1.580M |
| March 31, 2021 | -1.67M |
| December 31, 2020 | -1.671M |
| September 30, 2020 | -1.564M |
| June 30, 2020 | -1.615M |
| March 31, 2020 | -1.827M |
| December 31, 2019 | -1.555M |
| September 30, 2019 | -1.820M |
| June 30, 2019 | -2.177M |
| March 31, 2019 | -1.370M |
| December 31, 2018 | -2.188M |
| September 30, 2018 | -1.609M |
| June 30, 2018 | -1.456M |
| March 31, 2018 | -2.900M |
| December 31, 2017 | -2.722M |
| Date | Value |
|---|---|
| September 30, 2017 | -3.112M |
| June 30, 2017 | -3.295M |
| March 31, 2017 | -4.390M |
| December 31, 2016 | -5.001M |
| September 30, 2016 | -5.876M |
| June 30, 2016 | -5.044M |
| March 31, 2016 | -8.506M |
| December 31, 2015 | -9.652M |
| September 30, 2015 | -5.780M |
| June 30, 2015 | -4.545M |
| March 31, 2015 | -4.525M |
| December 31, 2014 | 0.8162M |
| September 30, 2014 | -3.748M |
| June 30, 2014 | -0.6434M |
| March 31, 2014 | -6.667M |
| December 31, 2013 | -16.60M |
| September 30, 2013 | -4.553M |
| June 30, 2013 | -2.377M |
| March 31, 2013 | -4.170M |
| December 31, 2012 | -1.921M |
| September 30, 2012 | -2.347M |
| June 30, 2012 | -3.833M |
| March 31, 2012 | -4.468M |
| December 31, 2011 | -3.452M |
| September 30, 2011 | -6.443M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-2.177M
Minimum
Jun 2019
-0.6634M
Maximum
Dec 2023
-1.286M
Average
-1.239M
Median
Dec 2021
Net Income (Quarterly) Benchmarks
| Insmed Inc | -186.06M |
| NeuroMetrix Inc | -1.650M |
| Intra-Cellular Therapies Inc | -28.58M |
| Rhythm Pharmaceuticals Inc | -41.63M |
| Amylyx Pharmaceuticals Inc | 4.731M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 0.629M |
| Enterprise Value | 83.15M |
| Earnings Yield | -3.04% |